Corona Remedies Q3 FY26 Results Approved; Newspaper Ad Published
CORONA Remedies Limited's Board approved the unaudited financial results for Q3 FY26 and nine months ended Dec 31, 2025. Newspaper advertisements of these results were published on February 03, 2026. The results are also available on the company's website.
This is a standard disclosure of financial results publication, which is a routine compliance activity. It does not introduce new information that is likely to significantly impact the stock price.
The announcement is a routine disclosure of financial results and their publication in newspapers, as required by SEBI regulations. It does not contain information that would significantly alter the company's valuation or future prospects.
CORONA Remedies Limited announced that the Board of Directors, in a meeting held on February 02, 2026, considered and approved the Unaudited Financial Results (Standalone and Consolidated) for the third quarter and nine months ended December 31, 2025.
As per Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has enclosed the newspaper advertisement of these results, which was published on February 03, 2026, in the Financial Express (English and Gujarati editions).
The extract of the newspaper publication is also available on the company's website at www.coronaremedies.com.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.